Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.

Sandor C., Robertson P., Lang C., Heger A., Booth H., Vowles J., Witty L., Bowden R., Hu M., Cowley SA., Wade-Martins R., Webber C.

While induced pluripotent stem cell (iPSC) technologies enable the study of inaccessible patient cell types, cellular heterogeneity can confound the comparison of gene expression profiles between iPSC-derived cell lines. Here, we purified iPSC-derived human dopaminergic neurons (DaNs) using the intracellular marker, tyrosine hydroxylase. Once purified, the transcriptomic profiles of iPSC-derived DaNs appear remarkably similar to profiles obtained from mature post-mortem DaNs. Comparison of the profiles of purified iPSC-derived DaNs derived from Parkinson's disease (PD) patients carrying LRRK2 G2019S variants to controls identified significant functional convergence amongst differentially-expressed (DE) genes. The PD LRRK2-G2019S associated profile was positively matched with expression changes induced by the Parkinsonian neurotoxin rotenone and opposed by those induced by clioquinol, a compound with demonstrated therapeutic efficacy in multiple PD models. No functional convergence amongst DE genes was observed following a similar comparison using non-purified iPSC-derived DaN-containing populations, with cellular heterogeneity appearing a greater confound than genotypic background.

DOI

10.1093/hmg/ddw412

Type

Journal article

Journal

Hum Mol Genet

Publication Date

01/02/2017

Volume

26

Pages

552 - 566

Keywords

Autopsy, Cells, Cultured, Clioquinol, Dopamine, Dopaminergic Neurons, Gene Expression Profiling, Gene Expression Regulation, Humans, Induced Pluripotent Stem Cells, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Mutation, Parkinson Disease, Rotenone, Transcriptome

Permalink Original publication